Conjectures and refutations on the mode of action of heparins: The limited importance of anti-factor Xa activity as a pharmaceutical mechanism and a yardstick for therapy

Haemostasis

Volumn 29, Issue 2-3, 1999, Pages 170-178

  Beguin S ^b   Welzel, D ^b   Al Dieri, R ^b   Hemker, H C ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b NONE

Author keywords

Factor Xa; Low molecular weight heparins; Thrombin

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; CALCIUM ION; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN ANTITHROMBIN COMPLEX; TISSUE FACTOR PATHWAY INHIBITOR;

BLOOD CLOTTING; CONFERENCE PAPER; DOSE RESPONSE; DRUG ACTIVITY; DRUG MECHANISM; HEPARINIZATION; HUMAN; LABORATORY DIAGNOSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL;

ANIMALS; ANTICOAGULANTS; FACTOR XA; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; THROMBOSIS;

EID: 0343484317     PISSN: 03010147     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (37)

1. Béguin S, Wielders S, Lormeau JC, Hemker HC: The mode of action of CY 216 and CY 222 in plasma. Thromb Haemost 1992;67:33-41.
2. Béguin S, Mardiguian J, Lindhout T, Hemker HC: The mode of action of low molecular weight heparin preparation (PK10169) and two of its major components on thrombin generation in plasma. Thromb Haemost 1989;61:30-34.
3. Béguin S, Lindhout T, Hemker HC: The mode of action of heparin in plasma. Thromb Haemost 1988;60: 457-462.
4. Hemker HC: The mode of action of heparin in plasma; in Verstraete M, Vermylen J, Lijnen HR, Arnout J (eds): Thrombosis and Haemostasis. Leuven, University Press, 1987, pp 17-36.
5. Walenga J, Petitou M, Lormeau JC, Samama M, Farced J, Choay J: Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges Thromb Res 1987;46:187-198.
6. Choay J, Petitou M, Lormeau JC, Sinay P, Casu B, Gatti G: Structure-activity relationship in heparin. A synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun 1985;128:134-140.
7. Béguin S, Choay J, Hemker HC: The action of a synthetic pentasaccharide on thrombin generation in whole plasma. Thromb Haemost 1989;61:397-401.
8. Thomas DP, Merton RE, Gray E, Barrowcliffe TW: The relative antithrombotic effectiveness of heparin, a low molecular weight heparin, and a pentasaccharide fragment in an animal model. Thromb Haemost 1989;61:204-207.
9. Barrowcliffe TW, Johnson EA, Thomas DP: Low Molecular Weight Heparin. Chichester, Wiley, 1992.
10. Béguin S, Dol F, Hemker HC: Factor IXa inhibition contributes to the heparin effect. Thromb Haemost 1991;66:306-309.
11. Yin ET, Wessler S, Stoll PJ: Biological properties of the naturally occurring plasma inhibitor to activated factor X. J Biol Chem 1971;246: 3703-3711.
12. Yin ET, Wessler S, Stoll PJ: Identity of plasma-activated factor X inhibitor with antithrombin III and heparin cofactor. J Biol Chem 1971;246: 3712-3719.
13. Merton RE, Thomas DP, Havercroft SJ, Barrowcliffe TW, Lindahl U: High and low affinity heparin compared with unfractioned heparin as antithrombotic drugs. Thromb Haemost 1984;51:254-256.
14. Ockelford PA, Carter CJ, Cerskus A, Smith CA, Hirsh J: Comparison of the in vivo hemorrhagic and antithrombotic effects of a low antithrombin-III affinity heparin fraction. Thromb Res 1982;27:679-690.
15. Zammit A, Dawes J: Low-affinity material does not contribute to the antithrombotic activity of Orgaran (Org 10172) in human plasma. Thromb Haemost 1994;71:759-767.
16. Barrowcliffe TW, Merton RE, Havercroft SJ, Thunberg L, Lindahl U, Thomas DP: Low-affinity heparin potentiates the action of high-affinity heparin oligosaccharides. Thromb Res 1984;34:125-134.
17. Lane DA, Denton J, Flynn AM, Thunberg L, Lindahl U: Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. Biochem J 1984; 218:725-732.
18. Lane DA, MacGregor IR, VanRoss M, Cella G, Kakkar VV: Molecular weight dependence of the anticoagulant properties of heparin: Intravenous and subcutaneous administration of fractionated heparins to man. Thromb Res 1979;16:651-662.
19. Ofosu FA, Sie P, Modi GJ, Fernandez F, Buchanan MR, Blajchman MA, Boneu B, Hirsh J: The inhibition of thrombin-dependent positive-feedback reactions is critical to the expression of the anticoagulant effect of heparin. Biochem J 1987; 243:579-588.
20. Béguin S, Lindhout T, Hemker HC: The effect of trace amounts of tissue factor on thrombin generation in platelet rich plasma. Its inhibition by heparin. Thromb Haemost 1989; 61:25-29.
21. Hemker HC, Béguin S, Kakkar VV: Can the haemorrhagic component of heparin be identified? Or an attempt at clean thinking on a dirty drug. Haemostasis 1996;26:117-126.
22. Bendetowicz AV, Béguin S, Caplain H, Hemker HC: Pharmacokinetics and pharmacodynamics of a low molecular weight heparin (enoxaparin) after subcutaneous injection. Comparison with unfractionated heparin. A three way cross over study in human volunteers. Thromb Haemost 1994;71:305-313.
23. Hemker HC, Béguin S: Standard-and method-independent units for heparin anticoagulant activities. Thromb Haemost 1993;70:724-728.
24. Kakkar VV, Cohen AT, Edmonson RA, Phillips MJ, Cooper DJ, Das SK, Maher KT, Sanderson RM, Ward VP, Kakkar S: Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. Lancet 1993;341:259-265.
25. deSwart CAM, Nijmeyer B, Andersson L, Holmer E, Verschoor L, Bouma BN, Sixma JJ: Elimination of high affinity heparin fractions, their anticoagulant and lipase activity. Blood 1984;6:836-842.
26. Boneu B, Buchanan MR, Caranobe C, Gabaig AM, Dupouy D, Sie P, Hirsh J: The disappearance of a low-molecular weight heparin fraction (CY 216) differs from standard heparin in rabbits. Thromb Res 1987; 46:845-853.
27. 2+ ions: Why the anti-Xa activity of LMW heparins is about two times overestimated. Thromb Haemost 1993;70:717-718.
28. Ødegaard OR, Lie M, Abildgaard U: Heparin co-factor activity measured with an amidolytic method. Thromb Res 1975;6:287-294.
29. Teien AN, Lien M, Abildgaard U: Assay of heparin in plasma using a chromogenic substrate. Thromb Res 1976;8:413-416.
30. Josso F, Béguin S: Changes in the antithrombin III activity at the interface plasma-phospholipids. Thromb Haemost 1981;46:285.
31. Speijer H, Billy D, Willems G, Hemker HC, Lindhout T: Inhibition of prothrombinase by antithrombin-heparin at a macroscopic surface. Thromb Haemost 1995;73:648-653.
32. Poller L, Thomson JM, Yee KF: Heparin and partial thromboplastin time, an international survey. Br J Haematol 1980;44:161-165.
33. van den Besselaar AMHP, Meeuwisse-Braun J, Bertina RM: Monitoring heparin therapy: Relationship between the activated partial thromboplastin time and heparin assays based on ex-vivo heparin samples. Thromb Haemost 1990;63: 16-23.
34. van Putten JJ, van de Ruit M, Beunis M, Hemker HC: Interindividual variation in relationship between plasma heparin concentration and the results of five heparin assays. Clin Chim Acta 1982;122:261-270.
35. Hemker HC, Wielders S, Béguin S: The thrombin potential. A parameter to assess the effect of antithrombotic drugs on thrombin generation; in Bounameaux H, Samama M, ten Cate JW (eds): Fraxiparine, Second International Symposium. Recent Pharmacological and Clinical Data. Stuttgart, Schattauer, 1990, pp 89-101.
36. Hemker HC, Wielders S, Kessels H, Béguin S: Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost 1993;70:617-624.
37. Wielders S, Mukherjee M, Michiels J, Rijkers DTS, Cambus J-P, Knebel RWC, Kakkar V, Hemker HC, Béguin S: The routine determination of the endogenous thrombin potential, first results in different forms of hyper-and hypocoagulability. Thromb Haemost 1997;77:629-636.